POC tests in microbial diagnostics: current status

Publication date: Available online 20 October 2015 Source:Methods in Microbiology Author(s): Luc Bissonnette, Michel G. Bergeron In January 2015, the Alere™ i Influenza A & B test became the first molecular test to receive a CLIA waiver, thereby leading the way to the detection of nucleic acids at point of care (POC). For the diagnosis and management of infectious diseases, there is an urgent need of such devices for controlling the morbidity and mortality of infections, and the evolution and progression of antimicrobial resistance. This chapter provides a snapshot of CLIA-waived tests marketed for the diagnosis of infectious diseases at POC and offers a mid-to-long overview of biomarkers, technologies, and organisational strategies anticipated to widen the scope of POC diagnostics in developing and industrialised countries.
Source: Methods in Microbiology - Category: Microbiology Source Type: research